和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

未开盘 03-20 16:08:10

21.850

-0.950

-4.17%

最高22.800	最低21.100	成交量325.81万
今开22.800	昨收22.800	日振幅7.46%
总市值188.95亿	流通市值188.95亿	总股本8.65亿
成交额7,050万	换手率0.38%	流通股本8.65亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":21.85,"timestamp":1679299690007,"preClose":22.8,"halted":0,"volume":3258140,"delay":0,"floatShares":864775340,"shares":864775340,"eps":-3.340572,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.95,"latestTime":"03-20 16:08:10","open":22.8,"high":22.8,"low":21.1,"amount":70502307,"amplitude":0.074561,"askPrice":21.9,"askSize":4000,"bidPrice":21.85,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-3.340572208366665,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1679362200000},"adr":0,"listingDate":1624982400000,"adjPreClose":22.8,"volumeRatio":1.053289,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2319856200","title":"和黄医药(00013.HK)授予武田呋喹替尼中国以外地区独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2319856200","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2319856200?lang=zh_CN&edition=full","pubTime":"2023-03-15 08:41","pubTimestamp":1678840860,"startTime":"0","endTime":"0","summary":"和黄医药公布，与武田药品工业株式会社之子公司就进一步推动呋喹替尼在中国以外地区的全球开发、商业化和生产达成的独家许可协议已完成交易。据此，和记黄埔医药(上海)将于短期内收到4亿美元，并可就监管、开发和商业销售里程碑收取额外可高达7.3亿美元的潜在付款，外加基于净销售额的特许权使用费。呋喹替尼为难治性转移性结直肠癌患者提供一种潜在的新治疗选择。呋喹替尼在内地、香港和澳门由和黄医药负责推出市场。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1251628/latest-news/HK6","is_publish_highlight":false},{"id":"2319076310","title":"和黄医药(00013)宣布与武田 (Takeda) 的呋喹替尼 (fruquintinib) 中国以外地区许可协议已完成交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2319076310","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2319076310?lang=zh_CN&edition=full","pubTime":"2023-03-14 21:33","pubTimestamp":1678800780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，继 2023 年 1 月 23 日的公告并完成包括反垄断审查在内的惯例成交条件后，与 Takeda Pharmaceutical Company Limited的子公司就进一步推动呋喹替尼在中国以外地区的全球开发、商业化和生产达成的独家许可协议已完成交易。呋喹替尼在中国内地、中国香港和中国澳门由和黄医药负责推出市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/891838.html","is_publish_highlight":false},{"id":"2319326706","title":"和黄医药(00013.HK)遭执行董事郑泽锋减持47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2319326706","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2319326706?lang=zh_CN&edition=full","pubTime":"2023-03-13 06:51","pubTimestamp":1678661495,"startTime":"0","endTime":"0","summary":"格隆汇3月13日丨根据联交所最新权益披露资料显示，2023年3月8日，和黄医药(00013.HK)遭执行董事郑泽锋(首席财务官)在场内以每股均价27.0222港元减持47万股，涉资约1270.04万港元。　　减持后，郑泽锋最新持股数目为263.39万股，持股比例由0.36%下降至0.30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2023/03/13065137395085.shtml","is_publish_highlight":false},{"id":"2318853246","title":"和黄医药(00013.HK)遭执行董事郑泽锋减持83万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2318853246","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2318853246?lang=zh_CN&edition=full","pubTime":"2023-03-10 06:40","pubTimestamp":1678401649,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨根据联交所最新权益披露资料显示，2023年3月7日，和黄医药(00013.HK)遭执行董事郑泽锋(首席财务官)在场内以每股均价27.1013港元减持83万股，涉资约2249.41万港元。减持后，郑泽锋最新持股数目为310.39万股，持股比例由0.45%下降至0.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303100640548417f41b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303100640548417f41b&s=b","is_publish_highlight":false},{"id":"2318632269","title":"港美两市双跌，核心产品陷入内卷的和黄医药(00013)又遭CFO减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2318632269","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2318632269?lang=zh_CN&edition=full","pubTime":"2023-03-09 19:09","pubTimestamp":1678360187,"startTime":"0","endTime":"0","summary":"业绩难以转移收支平衡压力经过疫情3年的增长，目前创新药板块已成为和黄医药的核心增长板块之一。截至2022年12月31日止年度，公司净开支为7.87亿美元，而2021年为5.51亿美元。数据显示，截至2022年12月31日，和黄医药年度净亏损为3.61亿美元，同比扩大85.38%。去年11月，和黄医药发布公告，宣布调整企业战略。这就意味着，在新的创新药产品获批之前，目前已上市的索凡替尼、呋喹替尼和赛沃替尼将成为和黄医药后续重要的业绩承压点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/889311.html","is_publish_highlight":false},{"id":"2317439593","title":"和黄医药(00013)出现大手卖出19.35万股，成交价$26.9，涉资520.515万","url":"https://stock-news.laohu8.com/highlight/detail?id=2317439593","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2317439593?lang=zh_CN&edition=full","pubTime":"2023-03-07 11:09","pubTimestamp":1678158540,"startTime":"0","endTime":"0","summary":"[大手成交]和黄医药(00013)在上午11:09出现大手卖出，成交量为19.35万，成交价为港币$26.9，涉资520.515万。至目前为止，股价跌0.37%，今日最高价为$27.35，而最低价为$26.65，总成交量为89.9万股，总成交金额港币$2.426千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2303073544/aamm-all-category","is_publish_highlight":false},{"id":"2317118673","title":"和黄医药3月3日获南向资金加仓129.60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2317118673","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2317118673?lang=zh_CN&edition=full","pubTime":"2023-03-06 09:32","pubTimestamp":1678066342,"startTime":"0","endTime":"0","summary":"3月3日, 南向资金增持和黄医药129.60万股。截止当日收盘，港股通共持有和黄医药8459.98万股，占流通股9.77%。和黄医药近5个交易日上涨7.33%，港股通累计增持224.15万股；近20个交易日下跌12.58%，港股通累计增持246.85万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030609344683527953&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030609344683527953&s=b","is_publish_highlight":false},{"id":"2316139409","title":"华创证券：维持和黄医药推荐评级 目标价35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2316139409","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2316139409?lang=zh_CN&edition=full","pubTime":"2023-03-03 09:48","pubTimestamp":1677808087,"startTime":"0","endTime":"0","summary":"华创证券发布研究报告称，维持和黄医药“推荐”评级，据业务进展更新调整盈利预测，预计2023-25年营业收入分别为7.33/7.63/8.69亿美元；归母净利润为-0.45/-0.12/0.44亿美元，目标价35港元，看好其强大的研发实力、临床执行力及商业化推进能力。研发开支3.869亿美元，截至2022年底现金及现金等价物和短期投资合计6.31亿美元。和黄医药将呋喹替尼海外权益授予武田，首付款高达4亿美元，交易总额11.3亿美元，金额在国产创新药海外授权交易中位居前列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-03/doc-imyipzuy7319064.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-03/doc-imyipzuy7319064.shtml","is_publish_highlight":false},{"id":"2316293137","title":"创新药挑起业绩大梁，和黄医药(00013)却离收支平衡点越来越远","url":"https://stock-news.laohu8.com/highlight/detail?id=2316293137","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2316293137?lang=zh_CN&edition=full","pubTime":"2023-03-02 19:38","pubTimestamp":1677757111,"startTime":"0","endTime":"0","summary":"与国内大多仿制起家的药企不同，而经过疫情3年的增长，目前创新药板块已成为和黄医药的核心增长板块，只是随着全球临床试验的开展，公司研发投入只增不减，“收支平衡”压力越来越大。创新药挑大梁，收支平衡压力增大在宣布了与武田制药达成的11亿美元Licence out大单后的一个月，和黄医药披露了其2022年年度财务业绩。滚动提交呋喹替尼用于治疗难治性转移性结直肠癌的新药上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/886149.html","is_publish_highlight":false},{"id":"2316934429","title":"华人健康：公司与山东济水阿胶有限公司、广州白云山和黄医药有限公司等众多公司均有业务合作，合作内容包括阿胶、鹿角胶、龟甲胶、西洋参、枸杞子等中药的采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2316934429","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2316934429?lang=zh_CN&edition=full","pubTime":"2023-03-02 19:04","pubTimestamp":1677755049,"startTime":"0","endTime":"0","summary":"同花顺（300033）金融研究中心3月2日讯，有投资者向华人健康提问， 请问公司和哪些中药企业有合作？公司回答表示，尊敬的投资者您好，公司与山东济水阿胶有限公司、广州白云山和黄医药有限公司等众多公司均有业务合作，合作内容包括阿胶、鹿角胶、龟甲胶、西洋参、枸杞子等中药的采购。感谢您的关注！点击进入互动平台 查看更多回复信息（责任编辑：张晓波 ）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030220111884152aa4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030220111884152aa4&s=b","is_publish_highlight":false},{"id":"2316011516","title":"招银国际：维持和黄医药买入评级 目标价37.49港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2316011516","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2316011516?lang=zh_CN&edition=full","pubTime":"2023-03-02 12:25","pubTimestamp":1677731100,"startTime":"0","endTime":"0","summary":"　　招银国际发布研究报告称，维持和黄医药“买入”评级，看好进一步的销售放量，以及核心产品的国际化潜力，调整目标价至37.49港元。公司2022年全年肿瘤产品销售实现+63%同比增长，达到1.25亿美元。公司预计2023年肿瘤产品销售收入将达到4.50-5.5亿美元，其中包括对武田制药4亿美元首付款的部分收入确认。呋喹替尼的海外权益已授权给武田制药，和黄医药将收到4亿美元首付款、高达7.3亿美元的里程碑付款、以及销售分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-02/doc-imyincct7761897.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2023-03-02/doc-imyincct7761897.shtml","is_publish_highlight":false},{"id":"2316603552","title":"*瑞信下调和黄医药(00013.HK)目标价至37.2元  评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2316603552","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2316603552?lang=zh_CN&edition=full","pubTime":"2023-03-02 10:28","pubTimestamp":1677724080,"startTime":"0","endTime":"0","summary":"(港股报价延迟最少十五分钟。沽空资料截至 2023-03-01 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173822691_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173822691_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1248754/latest-news/HK6","is_publish_highlight":false},{"id":"2316674159","title":"中金：维持和黄医药(00013)“跑赢行业”评级 目标价37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2316674159","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2316674159?lang=zh_CN&edition=full","pubTime":"2023-03-02 09:13","pubTimestamp":1677719613,"startTime":"0","endTime":"0","summary":"中金认为，未来和黄医药(00013)三款主要产品销售收入也将迎来持续增长。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20230302/20230302091406_55898.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20230302/20230302091406_55898.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/885746.html","is_publish_highlight":false},{"id":"2316656760","title":"【港股通】和黄医药(00013)绩后涨3.68% 去年营收同比增长20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2316656760","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2316656760?lang=zh_CN&edition=full","pubTime":"2023-03-01 10:22","pubTimestamp":1677637378,"startTime":"0","endTime":"0","summary":"和黄医药去年收入增长20%，早盘股价短线拉高后，维持高位震荡，最新报26.80港元，涨3.68%，成交额3856万港元。隔夜美股和黄医药收盘涨5.35%，报16.55美元，折合港币25.98港元。公司发布截至2022年12月31日止年度业绩，录得和黄医药应占净亏损3.61亿美元，同比扩大85.38%；基本每股ADS亏损2.13美元，上年同期亏损1.23美元。同期，收入4.26亿美元，同比增长19.73%；研发开支为3.869亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=41779578a6c99a826c2c36bdb8a0b6c5","is_publish_highlight":false},{"id":"2316655688","title":"快讯 | 和黄医药：2022年总收入4.264亿美元，股东应占净亏损3.61亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2316655688","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2316655688?lang=zh_CN&edition=full","pubTime":"2023-03-01 09:56","pubTimestamp":1677635804,"startTime":"0","endTime":"0","summary":"财经网产经讯 和黄医药2月28日发布2022年全年业绩，2022年公司总收入4.264亿美元，同比增长20%；和黄医药应占净亏损3.61亿美元，同比扩大85.38%；每股应占净亏损0.43美元。公告显示，2022年总收入增长系受三款自主研发的肿瘤药物于中国的商业化进展所驱动。肿瘤/免疫业务综合收入增长37%至1.638亿美元。沃瑞沙2022年的市场销售额增长159%至4120万美元，该药物为中国首个选择性MET抑制剂，自2023年3月1日起将纳入国家医保药品目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030109582782b93424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023030109582782b93424&s=b","is_publish_highlight":false},{"id":"2316065365","title":"港股异动 | 和黄医药(00013)升5% 22年总收入同比增20% 净亏损3.61亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2316065365","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2316065365?lang=zh_CN&edition=full","pubTime":"2023-03-01 09:39","pubTimestamp":1677634768,"startTime":"0","endTime":"0","summary":"和黄医药(00013)绩后温和走强，盘初升约5%。2022年，公司实现总收入4.264亿美元，同比增长20%；股东应占净亏损3.61亿美元，同比扩大85.38%。期内，肿瘤/免疫业务综合收入增长37%至1.638亿美元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20230301/20230301094438_66991.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20230301/20230301094438_66991.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/884900.html","is_publish_highlight":false},{"id":"2316658055","title":"港股异动 | 和黄医药(0013.HK)涨超5% 2022年度总收入增长20% 与武田制药达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2316658055","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2316658055?lang=zh_CN&edition=full","pubTime":"2023-03-01 09:36","pubTimestamp":1677634605,"startTime":"0","endTime":"0","summary":"格隆汇3月1日丨和黄医药(0013.HK)涨超5%，报27.3港元，总市值236亿港元。该公司昨日盘后公布年度业绩，截至2022年12月31日止年度收入为4.264亿美元，而2021年为3.561亿美元；其中，肿瘤/免疫业务综合收入增长37%(按固定汇率计算：41%)至1.638亿美元；股东应占净亏损为3.608亿美元，而2021年为1.946亿美元。公告称，2023年新年伊始，武田制药宣布与武田制药达成一项重要的许可协议，即于中国以外地区对呋喹替尼开展全球开发、商业化和生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303010938058263ef04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303010938058263ef04&s=b","is_publish_highlight":false},{"id":"2316580686","title":"和黄医药(00013.HK)升逾4% 去年收入增近两成","url":"https://stock-news.laohu8.com/highlight/detail?id=2316580686","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2316580686?lang=zh_CN&edition=full","pubTime":"2023-03-01 09:36","pubTimestamp":1677634560,"startTime":"0","endTime":"0","summary":"和黄医药(00013.HK) 今日高开2.13%，最高见27.4元。现报27元，升4.45%，成交50.85万股，涉资1,366.72万元。和黄医药公布去年亏损扩大至3.61亿美元，收入按年升近两成至4.26亿美元。(mn/w)(港股报价延迟最少十五分钟。沽空资料截至 2023-02-28 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173826807_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1248352/latest-news/HK6","is_publish_highlight":false},{"id":"2316634081","title":"港股公告掘金 | 精品零售龙头把握复苏环境，积极拓展海外，产品结构升级大幅提升毛利率","url":"https://stock-news.laohu8.com/highlight/detail?id=2316634081","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2316634081?lang=zh_CN&edition=full","pubTime":"2023-03-01 08:10","pubTimestamp":1677629435,"startTime":"0","endTime":"0","summary":"品牌升级战略对产品毛利率仍有提升空间。截至22Q4公司门店合计5440家，其中Miniso国内3325家，海外2115家，TOPTOY117家。其中呋喹替尼治疗结直肠癌的FRESCO-2 III期临床达到OS主要终点，死亡风险降低34%。2022年受局部疫情影响，二期投产带来的客流红利尚未显现。岛内免税运营商竞争加剧，国有资产地位提升公司议价能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/884859.html","is_publish_highlight":false},{"id":"2314309508","title":"名创优品2022下半年净利增长127% 和黄医药去年亏损近30亿港元｜港股2月28日公告精选","url":"https://stock-news.laohu8.com/highlight/detail?id=2314309508","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2314309508?lang=zh_CN&edition=full","pubTime":"2023-02-28 21:09","pubTimestamp":1677589750,"startTime":"0","endTime":"0","summary":"截至2022年12月31日，包括中国和海外市场在内的名创优品门店总数达5440家，同比增加395家。2022肿瘤及免疫业务综合收入同比增长达37%，研发开支为3.87亿美元，较2021年的2.99亿美元进一步增长。主要由于2021年所持恒大地产股权发生减值损失，而2022年并无计提。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302282109358263ad88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302282109358263ad88&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.1396},{"period":"3month","weight":0.0224},{"period":"6month","weight":0.2193},{"period":"1year","weight":-0.2165},{"period":"ytd","weight":-0.05}],"websiteUrl":"http://www.hutch-med.com","compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":-0.0622},{"period":"3month","weight":0.0035},{"period":"6month","weight":0.0403},{"period":"1year","weight":-0.0922},{"period":"ytd","weight":-0.0133}],"name":"和黄医药","description":"和黄医药（中国）有限公司（原名：和黄中国医药科技有限公司）是一家主要从事药品制造及销售的投资控股公司。连同其附属公司，该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法，包括涵盖药物发现、开发、生产及监管职能的研发活动，以及支持研发业务的行政活动，还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","exchange":"SEHK","nameEN":"HUTCHMED","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}